BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Korean Association for the Study of the Liver (KASL). 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. Clin Mol Hepatol 2018;24:169-229. [PMID: 30092624 DOI: 10.3350/cmh.2018.1004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Park YJ, Woo HY, Heo J, Park SG, Hong YM, Yoon KT, Kim DU, Kim GH, Kim HH, Song GA, Cho M. Real-Life Effectiveness and Safety of Glecaprevir/Pibrentasvir for Korean Patients with Chronic Hepatitis C at a Single Institution. Gut Liver 2021;15:440-50. [PMID: 32839365 DOI: 10.5009/gnl19393] [Reference Citation Analysis]
2 Oh JH, Goh MJ, Park Y, Kim J, Kang W, Sinn DH, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Paik YH. Different Performance of Liver Stiffness Measurement According to Etiology and Outcome for the Prediction of Liver-Related Events. Dig Dis Sci 2021;66:2816-25. [PMID: 32897445 DOI: 10.1007/s10620-020-06591-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Jang ES, Kim KA, Kim YS, Kim IH, Lee BS, Lee YJ, Chung WJ, Jeong SH. Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose. Gut Liver 2020;14:775-82. [PMID: 32000468 DOI: 10.5009/gnl19260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Lee HW, Han DH, Shin HJ, Lee JS, Kim SU, Park JY, Kim DY, Ahn SH, Kim BK. Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals. Cancers (Basel) 2020;12:E3414. [PMID: 33217965 DOI: 10.3390/cancers12113414] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
5 Yoon JH, Kim SM, Kang G, Kim HJ, Jun CH, Choi SK. A case report of glecaprevir/pibrentasvir-induced severe hyperbilirubinemia in a patient with compensated liver cirrhosis. Medicine (Baltimore) 2019;98:e17343. [PMID: 31574875 DOI: 10.1097/MD.0000000000017343] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Cho HJ, Park E. Development and Evaluation of an Antiviral Agent Medication Adherence Education Program for Patients with Chronic Hepatitis C. Int J Environ Res Public Health 2020;17:E6518. [PMID: 32906842 DOI: 10.3390/ijerph17186518] [Reference Citation Analysis]
7 Park SK, Choi CH, Chun J, Lee H, Kim ES, Park JJ, Park CH, Lee BI, Jung Y, Park DI, Kim DY, Park H, Jeen YT;  IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Prevention and management of viral hepatitis in inflammatory bowel disease: a clinical practice guideline by the Korean Association for the Study of Intestinal Diseases. Intest Res. 2020;18:18-33. [PMID: 32013312 DOI: 10.5217/ir.2019.09155] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Smirne C, D'Avolio A, Bellan M, Gualerzi A, Crobu MG, Pirisi M. Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose. Pharmacol Res Perspect 2021;9:e00811. [PMID: 34152088 DOI: 10.1002/prp2.811] [Reference Citation Analysis]
9 Jang ES, Kim KA, Kim YS, Kim IH, Lee BS, Lee YJ, Chung WJ, Jeong SH. Effectiveness and safety of elbasvir/grazoprevir in Korean patients with hepatitis C virus infection: a nationwide real-world study. Korean J Intern Med 2021;36:S1-8. [PMID: 32539296 DOI: 10.3904/kjim.2019.357] [Reference Citation Analysis]
10 Lee MW, Kang D, Lim HK, Cho J, Sinn DH, Kang TW, Song KD, Rhim H, Cha DI, Lu DSK. Updated 10-year outcomes of percutaneous radiofrequency ablation as first-line therapy for single hepatocellular carcinoma < 3 cm: emphasis on association of local tumor progression and overall survival. Eur Radiol 2020;30:2391-400. [DOI: 10.1007/s00330-019-06575-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
11 Yeon JE. Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: Comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL. Clin Mol Hepatol 2018;24:278-93. [PMID: 29716179 DOI: 10.3350/cmh.2018.1002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
12 Lim DH, Jeong JY, Nam S, Choi J, Kwon HC, Yoon YB, Kim Y, Chin B. Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea. J Korean Med Sci 2021;36:e308. [PMID: 34845874 DOI: 10.3346/jkms.2021.36.e308] [Reference Citation Analysis]
13 Kim YA, Kang D, Moon H, Sinn D, Kang M, Woo SM, Chang YJ, Park B, Kong SY, Guallar E, Shin SY, Gwak G, Back JH, Lee ES, Cho J. Survival in untreated hepatocellular carcinoma: A national cohort study. PLoS One 2021;16:e0246143. [PMID: 33539397 DOI: 10.1371/journal.pone.0246143] [Reference Citation Analysis]
14 Park SJ, Kim AR, Choe WH, Kim JH, Yoo BC, Kwon SY. The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study. Korean J Gastroenterol 2018;72:197-204. [PMID: 30419644 DOI: 10.4166/kjg.2018.72.4.197] [Reference Citation Analysis]
15 Yeon JE. Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans? Clin Mol Hepatol 2018;24:294-6. [PMID: 30200750 DOI: 10.3350/cmh.2018.1009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
16 Sinn DH, Kang D, Guallar E, Hong YS, Cho J, Gwak G. Modest alcohol intake and mortality in individuals with elevated alanine aminotransferase levels: a nationwide cohort study. BMC Med 2022;20. [DOI: 10.1186/s12916-021-02215-x] [Reference Citation Analysis]
17 Sinn DH, Kang D, Cho SJ, Paik SW, Guallar E, Cho J, Gwak GY. Risk of hepatocellular carcinoma in individuals without traditional risk factors: development and validation of a novel risk score. Int J Epidemiol 2020;49:1562-71. [PMID: 32725117 DOI: 10.1093/ije/dyaa089] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
18 Morishita N, Sakamori R, Yamada T, Kai Y, Tahata Y, Urabe A, Yamada R, Kodama T, Hikita H, Doi Y, Tamura S, Hagiwara H, Imai Y, Iio S, Tatsumi T, Takehara T. Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection. PLoS One 2020;15:e0234811. [PMID: 32544182 DOI: 10.1371/journal.pone.0234811] [Reference Citation Analysis]
19 Lee DH, Ryu SH, Myung HJ, Shin YJ, Lee SH, Park TY, Moon JS. Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals. Korean J Gastroenterol 2021;77:88-91. [PMID: 33633000 DOI: 10.4166/kjg.2020.145] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Bahadur Gurung A, Ajmal Ali M, Lee J, Abul Farah M, Mashay Al-Anazi K. Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme. J King Saud Univ Sci 2020;32:2845-53. [PMID: 32837113 DOI: 10.1016/j.jksus.2020.07.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
21 Sinn DH, Kang D, Hong YS, Koh KC, Guallar E, Cho J, Gwak GY. Prior antiviral treatment and mortality among patients with hepatitis C virus-related hepatocellular carcinoma: A national cohort study. PLoS One 2021;16:e0255624. [PMID: 34343200 DOI: 10.1371/journal.pone.0255624] [Reference Citation Analysis]